Platt Investment Counsel LLC Buys New Position in Bristol Myers Squibb Company $BMY

Platt Investment Counsel LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 8,525 shares of the biopharmaceutical company’s stock, valued at approximately $491,000. Bristol Myers Squibb comprises 0.3% of Platt Investment Counsel LLC’s holdings, making the stock its 10th biggest holding.

Other large investors have also modified their holdings of the company. Thurston Springer Miller Herd & Titak Inc. increased its holdings in shares of Bristol Myers Squibb by 65.0% during the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 2,607 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 1,027 shares in the last quarter. Foresight Capital Management Advisors Inc. raised its position in shares of Bristol Myers Squibb by 32.4% in the 2nd quarter. Foresight Capital Management Advisors Inc. now owns 48,144 shares of the biopharmaceutical company’s stock valued at $2,774,000 after purchasing an additional 11,774 shares during the last quarter. Trust Point Inc. boosted its stake in Bristol Myers Squibb by 51.8% in the 2nd quarter. Trust Point Inc. now owns 13,912 shares of the biopharmaceutical company’s stock worth $802,000 after purchasing an additional 4,748 shares in the last quarter. Castle Rock Wealth Management LLC grew its position in Bristol Myers Squibb by 3.2% during the 2nd quarter. Castle Rock Wealth Management LLC now owns 47,869 shares of the biopharmaceutical company’s stock worth $2,702,000 after purchasing an additional 1,506 shares during the last quarter. Finally, Elevation Wealth Partners LLC grew its position in Bristol Myers Squibb by 22.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 1,417 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 260 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades improve sentiment. Argus upgraded BMY to Buy, while Zacks raised the stock to a Rank #2 (Buy), citing improving earnings prospects. These recommendations may attract additional income- and value-oriented investors. Argus Upgrades Bristol Myers Squibb to Buy Bristol Myers Moves to Buy
• Positive Sentiment: Recent earnings exceeded expectations. Bristol Myers Squibb reported quarterly earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue of $12.97 billion surpassed the $11.74 billion forecast. Revenue also grew 5.7% year over year, reinforcing the positive earnings narrative discussed on the company’s earnings call. Bristol Myers Squibb Q2 Earnings Call
• Positive Sentiment: Pipeline and research investments provide longer-term support. BMY is launching a real-world study examining luspatercept use in anemia care, while an expanded partnership with Schrödinger will deploy AI drug-discovery tools across BMS teams. These initiatives could improve evidence generation and help accelerate future medicines. Bristol Myers Squibb Tracks Luspatercept Use Schrödinger and BMS Expand Partnership
• Neutral Sentiment: Broader optimism around potential biotech and pharmaceutical catalysts may support sector sentiment, but the cited drug-development opportunities are not specific to BMY. New Drugs Could Fuel Pharma Stock Gains

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Citigroup reaffirmed a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. JPMorgan Chase & Co. upped their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, July 30th. Finally, TD Cowen started coverage on Bristol Myers Squibb in a research report on Wednesday. They set a “buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Stock Performance

BMY opened at $64.63 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.10. The firm has a 50 day moving average of $58.71 and a two-hundred day moving average of $58.64. The firm has a market capitalization of $132.02 billion, a PE ratio of 14.24, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.96 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.